TMO
Thermo Fisher Scientific Inc.
- Operating income, 2025
- $7.7B
- YoY, 2025
- +5.6%
- 5-year CAGR
- −0.1%
- 10-year CAGR
- +12.7%
Operating income
Operating income by fiscal year
| Period | Operating income | YoY |
|---|---|---|
| 2025 | $7.7B | +5.6% |
| 2024 | $7.3B | +7.0% |
| 2023 | $6.9B | −18.3% |
| 2022 | $8.4B | −16.3% |
| 2021 | $10.0B | +28.7% |
| 2020 | $7.8B | +69.7% |
| 2019 | $4.6B | +21.4% |
| 2018 | $3.8B | +27.8% |
| 2017 | $3.0B | +20.4% |
| 2016 | $2.5B | +5.2% |
| 2015 | $2.3B | −6.7% |
| 2014 | $2.5B | +55.5% |
| 2013 | $1.6B | +8.6% |
| 2012 | $1.5B | +18.5% |
| 2011 | $1.3B | +5.3% |
| 2010 | $1.2B | +18.6% |
| 2009 | $1.0B | −18.5% |
| 2008 | $1.2B | +26.2% |
| 2007 | $974M | — |